Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC17A5 | Q9NRA2 | 1/20 | 0.53 |
| ▸ | PPARA | Q07869 | 3/20 | 0.49 |
| ▸ | PPARG | P37231 | 1/20 | 0.49 |
| ▸ | TNF | P01375 | 1/20 | 0.49 |
| ▸ | MDM4 | O15151 | 2/20 | 0.48 |
| ▸ | TP53 | P04637 | 2/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.47 |
| ▸ | CASP3 | P42574 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 1/20 | 0.46 |
| ▸ | TDO2 | P48775 | 1/20 | 0.46 |
| ▸ | PTPN1 | P18031 | 2/20 | 0.45 |
| ▸ | TLR2 | O60603 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17446645 | 0.89 | HDAC1 (0.57) | SLC17A5PPARAPPARGTNFMDM4 | |
| SCHEMBL17446655 | 0.85 | HDAC1 (0.50) | SLC17A5HDAC1HDAC2IDO1PTPN1 | |
| SCHEMBL29908094 | 0.84 | SLC17A5 (0.61) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL29401307 | 0.84 | SLC17A5 (0.61) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL119188 | 0.84 | SLC17A5 (0.61) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL27620508 | 0.84 | SLC17A5 (0.61) | SLC17A5PPARAPPARGMDM4TP53 | |
| SCHEMBL15788337 | 0.84 | SLC17A5 (0.54) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL15788342 | 0.84 | SLC17A5 (0.54) | SLC17A5MDM4TP53CASP3TLR2 | |
| SCHEMBL1486194 | 0.83 | SLC17A5 (0.58) | SLC17A5TNFMDM4TP53CASP3 | |
| SCHEMBL29398108 | 0.83 | SLC17A5 (0.58) | SLC17A5TNFMDM4TP53CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215985-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | ORAGENICS, INC. | 2009-08-27 | — | — | US | disclosed |
| US-7521529-B2 | Differentially protected orthogonal lanthionine technology | ORAGENICS, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-20070037963-A1 | Lantibiotics; biosynthesis; solid phase synthesis; deblocking, deprotecting | ORAGENICS, INC. | 2007-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215985-A1 | DIFFERENTIALLY PROTECTED ORTHOGONAL LANTHIONINE TECHNOLOGY | VIP, LGMN, LNPEP | SLC17A5 1006/4885PPARA 3764/4885PPARG 4776/4885 |
| US-20070037963-A1 | Lantibiotics; biosynthesis; solid phase synthesis; deblocking, deprotecting | VIP, NISCH, COASY | SLC17A5 2377/4885PPARA 4128/4885PPARG 4757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.